Bradley J. Tandy Acquires 3,200 Shares of Enovis (NYSE:ENOV) Stock

Key Points

• SVP Bradley Tandy purchased 3,200 shares of Enovis at an average price of $31.41, increasing his ownership by 7.94% and bringing his total shares to 43,515.
• Enovis reported earnings of $0.79 per share for the last quarter, surpassing analyst expectations, and the company anticipates an EPS of 2.79 for the current fiscal year.
• Analysts have recently adjusted their price targets for Enovis, with estimates ranging from $41.00 to $57.00, reflecting a consensus target price of $51.00.

Enovis Corporation (NYSE:ENOV - Get Free Report) SVP Bradley J. Tandy purchased 3,200 shares of the company's stock in a transaction on Friday, August 22nd. The stock was purchased at an average price of $31.41 per share, for a total transaction of $100,512.00. Following the purchase, the senior vice president directly owned 43,515 shares of the company's stock, valued at $1,366,806.15. This trade represents a 7.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Enovis Price Performance

Shares of NYSE ENOV traded up $0.29 during mid-day trading on Friday, reaching $30.88. 934,252 shares of the company traded hands, compared to its average volume of 1,151,601. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.83. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The firm has a market cap of $1.77 billion, a PE ratio of -2.17 and a beta of 1.70. The stock has a fifty day simple moving average of $30.06 and a 200-day simple moving average of $33.55.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The business had revenue of $564.50 million for the quarter, compared to analyst estimates of $555.80 million. During the same quarter last year, the business earned $0.62 earnings per share. The business's revenue for the quarter was up 7.5% on a year-over-year basis. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Equities research analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Institutional Trading of Enovis

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Enovis by 11.3% in the 1st quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company's stock worth $233,356,000 after purchasing an additional 621,069 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Enovis by 191.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company's stock worth $26,772,000 after purchasing an additional 532,648 shares during the period. Paradigm Capital Management Inc. NY boosted its stake in Enovis by 2,566.0% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 533,200 shares of the company's stock worth $23,397,000 after purchasing an additional 513,200 shares during the period. AQR Capital Management LLC boosted its stake in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company's stock worth $15,627,000 after purchasing an additional 434,646 shares during the period. Finally, Boston Partners boosted its stake in Enovis by 42.4% in the 2nd quarter. Boston Partners now owns 1,382,724 shares of the company's stock worth $43,352,000 after purchasing an additional 411,744 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ENOV shares. Evercore ISI lowered their price objective on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Wells Fargo & Company lowered their price objective on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. UBS Group reduced their target price on shares of Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a report on Friday, August 8th. JMP Securities reduced their target price on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Finally, Canaccord Genuity Group reduced their target price on shares of Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $51.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.